ArticleFrontiers in immunology2025
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Induction of complete pathological response by immunochemotherapy in stage IIIA-N2 patients with SMARCA4-deficient lung adenocarcinoma: a case report.AME case reports · 2026Article
- Neoadjuvant PD-1/VEGF bispecific antibody combined with chemotherapy for locally advanced pulmonary lymphoepithelioma-like carcinoma achieving pathological complete response: a case report and literature review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Real-world data on neoadjuvant therapy for stage I-III non-small cell lung cancer (NSCLC) is limited. This study evaluates the efficacy and safety of neoadjuvant chemotherapy alone versus chemotherapy combined with immunotherapy, focusing on pathological response, imaging outcomes, event-free survival (EFS), and adverse events. Additionally, a prognostic model for EFS is established. Methods: Data from 134 NSCLC patients who received neoadjuvant therapy were analyzed. Pathological response rates, objective response rate(ORR), EFS and adverse events were compared between the two groups. Independent prognostic factors were identified using logistic and Cox regression analyses, and a predictive model was constructed and evaluated using nomograms, Receiver Operating Characteristic(ROC) curves, calibration curves, and Decision Curve Analysis(DCA) curves. Results: 1.The chemotherapy combined with immunotherapy group showed higher Pathological Complete Response (pCR) (48.8% vs. 12.5%) and ORR (80.2% vs. 47.9%) compared to the chemotherapy group ( Conclusion: Neoadjuvant chemotherapy combined with immunotherapy significantly improves pCR rates, ORR, and EFS compared to chemotherapy alone, with manageable adverse events. The predictive model provides valuable insights for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.